Sunday, September 27, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 3, 2026

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

View original at finance.yahoo.com
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • KIM-1 and NGAL enable earlier, more precise detection of CKD than traditional methods, improving the potential for timely intervention and better patient outcomes

    80% confidence
  • The CKD market size in the 7MM was approximately USD 4.8 billion in 2024 and is expected to increase further by 2034

    80% confidence
  • Zibotentan/dapagliflozin combination has the potential to reduce mortality and delay the onset of end-stage kidney disease (ESKD)

    80% confidence
  • Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment

    80% confidence
  • Despite improved outcomes, current therapies only delay progression and cannot halt or reverse CKD, highlighting a major and persistent unmet need

    80% confidence
  • The United States accounts for the largest market size of chronic kidney disease, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan

    80% confidence
  • No current medications can reverse CKD

    80% confidence
  • The CKD therapy market includes RAAS inhibitors as the standard of care and the rapidly growing use of SGLT-2 inhibitors such as FARXIGA and JARDIANCE as emerging front-line options

    80% confidence
  • The distribution of End-Stage Kidney Disease (ESKD) cases across the 7MM indicates that the number of patients on dialysis exceeds that of those receiving kidney transplants

    80% confidence
  • In 2024, there were approximately 82 million prevalent cases of CKD in the 7MM

    80% confidence
  • CKD cases are projected to increase further over the forecast period (2025-2034) due to the aging population

    80% confidence
  • The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations

    80% confidence
  • In 2024, there were nearly 14.5 million total diagnosed cases of CKD in the 7MM

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight — Source | Via News | Via News